MicroRNAs and their delivery in diabetic fibrosis.
Chronic kidney disease
Diabetes
Fibrosis
Nanotechnology
Noncoding RNA
microRNA
microRNA-based therapeutics
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
19
03
2021
revised:
21
09
2021
accepted:
04
11
2021
pubmed:
13
11
2021
medline:
19
3
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
The global prevalence of diabetes mellitus was estimated to be 463 million people in 2019 and is predicted to rise to 700 million by 2045. The associated financial and societal costs of this burgeoning epidemic demand an understanding of the pathology of this disease, and its complications, that will inform treatment to enable improved patient outcomes. Nearly two decades after the sequencing of the human genome, the significance of noncoding RNA expression is still being assessed. The family of functional noncoding RNAs known as microRNAs regulates the expression of most genes encoded by the human genome. Altered microRNA expression profiles have been observed both in diabetes and in diabetic complications. These transcripts therefore have significant potential and novelty as targets for therapy, therapeutic agents and biomarkers.
Identifiants
pubmed: 34767865
pii: S0169-409X(21)00438-5
doi: 10.1016/j.addr.2021.114045
pii:
doi:
Substances chimiques
Biomarkers
0
Drug Carriers
0
Hypoglycemic Agents
0
MicroRNAs
0
Nanoparticle Drug Delivery System
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114045Subventions
Organisme : Medical Research Council
ID : MR/K010492/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T002263/1
Pays : United Kingdom
Organisme : Department of Health
ID : II-LA-0712-20003
Pays : United Kingdom
Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TB and DF are inventors for patent WO/2017/129977 Chronic Kidney Disease Diagnostic. LD is the recipient of PhD studentship co-funding from Regulus Therapeutics and GSK.